Overview

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Status:
Recruiting
Trial end date:
2025-02-25
Target enrollment:
Participant gender:
Summary
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca